Physician profile
Deepak Gupta
NPI 1811990344
$7,826.94
in general payments reported to CMS, 2019-2025
27 companies · $2,605 in 2025
The $2,605 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.60 · 2023: $2,550 · 2024: $2,641 · 2025: $2,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,410 · Education: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,410.39 |
| Education | $385.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,280.12 | 2022-2025 | |
| Amgen INC. | $1,222.80 | 2023-2025 | Evenity, Enbrel, Prolia |
| Janssen Biotech, INC. | $1,064.30 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $785.54 | 2023-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $740.20 | 2023-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $335.28 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Glaxosmithkline, LLC. | $251.17 | 2023-2025 | Benlysta |
| Pfizer INC. | $248.19 | 2024-2025 | |
| Horizon Therapeutics Plc | $208.67 | 2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $201.21 | 2024-2025 | Lupkynis |
| Lilly USA, LLC | $193.00 | 2023 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $185.40 | 2023-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $177.97 | 2024-2025 | Orencia, Sotyktu |
| Novartis Pharmaceuticals Corporation | $164.33 | 2024-2025 | |
| Genzyme Corporation | $138.87 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $108.74 | 2024-2025 | Idacio |
| Depuy Synthes Sales INC. | $105.35 | 2023-2025 | Monovisc |
| Radius Health, INC. | $83.58 | 2023-2025 | Tymlos |
| Sobi, INC | $76.33 | 2023-2024 | |
| Organon LLC | $54.53 | 2023 | Renflexis, Hadlima |
| Kiniksa Pharmaceuticals International, Plc | $48.59 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.30 | 2023-2024 | Ofev, Cyltezo |
| Alexion Pharmaceuticals, INC. | $38.58 | 2024-2025 | Strensiq |
| Octapharma USA, INC. | $24.25 | 2025 | Octagam Immune Globulin (Human) |
| Biogen, INC. | $20.42 | 2023 | Tysabri |
| Bioventus LLC | $16.03 | 2023 | Durolane |
| Genentech USA, INC. | $14.19 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.